MANE vs IMVT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MANE · Veradermics$138.78 ▲ 7.92%
IMVT · Immunovant$30.53 ▲ 7.54%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MANE +267.6%
- IMVT +21.4%
Head to head
| Metric | MANE | IMVT |
|---|---|---|
| Price | $138.78 | $30.53 |
| Change today | ▲ 7.92% | ▲ 7.54% |
| Market cap | $5.80B | $6.31B |
| Return, 3 months | +25.3% | -23.5% |
| Return, year to date | – | +20.1% |
| Return, 1 year | – | +30.7% |
| P/E (TTM) | -55.6 | -10.9 |
| P/B | 7.1 | 8.6 |
| P/E percentile vs own 5y | 2nd | 48th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -50.2% | -27.0% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -12.8% | -80.1% |
| Analyst target vs. price | +21.8% | +63.1% |
| Analyst buy share | 100% | 80% |
| RSI (14) | 58 | 51 |
| 30-day volatility | 82.7% | 44.8% |
| Max drawdown, 1 year | -24.8% | -40.5% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IMVT is the largest of the group by market value.
- MANE carries the lowest trailing P/E.
- IMVT has been the calmest stock over the last 30 days.